SRZN Key Statistics, Chart & Performance
The current stock price of SRZN is 21.25 USD. In the past month the price increased by 6.41%. In the past year, price increased by 104.13%.
SRZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRZN. When comparing the yearly performance of all stocks, SRZN is one of the better performing stocks in the market, outperforming 97% of all stocks.
SRZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRZN. While SRZN seems to be doing ok healthwise, there are quite some concerns on its profitability.
SRZN Financial Highlights
Over the last trailing twelve months SRZN reported a non-GAAP Earnings per Share(EPS) of -22.34. The EPS decreased by -110.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SRZN Forecast & Estimates
8 analysts have analysed SRZN and the average price target is 37.74 USD. This implies a price increase of 77.6% is expected in the next year compared to the current price of 21.25.
For the next year, analysts expect an EPS growth of 21.3% and a revenue growth -31.51% for SRZN
SRZN Ownership
SRZN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.08 | 383.716B | ||
| AMGN | AMGEN INC | 16.32 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.25 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SRZN
Company Profile
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Company Info
SURROZEN INC
171 Oyster Point Blvd, Suite 400
South San Francisco CALIFORNIA US
CEO: Gad Soffer
Employees: 40
Phone: 16504752820
SURROZEN INC / SRZN FAQ
What does SURROZEN INC do?
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 40 full-time employees. The company went IPO on 2020-11-23. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
What is the stock price of SURROZEN INC today?
The current stock price of SRZN is 21.25 USD. The price decreased by -10.15% in the last trading session.
What is the dividend status of SURROZEN INC?
SRZN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRZN stock?
SRZN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SRZN stock?
SRZN stock is listed on the Nasdaq exchange.
How is the market expecting SRZN stock to perform?
8 analysts have analysed SRZN and the average price target is 37.74 USD. This implies a price increase of 77.6% is expected in the next year compared to the current price of 21.25.
Is SURROZEN INC (SRZN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SRZN.